Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

PT Etana Biotechnologies Indonesia

Request full access

Engaged in manufacturing, R&D and marketing of recombinant gene-technology, monoclonal antibody (MAB’s) drugs and vaccines

IndonesiaFounded 2014Biotech & Life Sciences

About PT Etana Biotechnologies Indonesia

Established in 2014 by founder Nathan Tirtana, PT Etana Biotechnologies Indonesia (Etana) is a biopharmaceutical company focused on developing and commercializing biologic drugs for the Southeast Asian market. The company operates in research, development, manufacturing, and marketing of therapies for oncology, autoimmune disorders, metabolic diseases, and other life-threatening conditions. Etana's business model centers on making treatments more accessible and affordable through local production, aligning with Indonesian government health programs.

Etana has positioned itself in the region by becoming the first pharmaceutical entity in ASEAN with mRNA technology capabilities. This platform allows for rapid development of new vaccines and other biopharmaceutical products. A significant milestone was the inauguration of its biopharmaceutical factory in the Pulogadung Industrial Estate, East Jakarta, in October 2022, an event attended by the President of the Republic of Indonesia. This facility adheres to international Good Manufacturing Practices (cGMP) and has received halal certification, enabling the production of a wide range of biologic therapies. The company has received multiple rounds of funding from international investors, including DEG, Yunfeng Capital, HighLight Capital, and East Ventures, to expand its product pipeline and manufacturing capacity, particularly in oncology.

The company's product portfolio includes treatments for oncology, nephrology, vaccines, and metabolic conditions. Key products include a bevacizumab biosimilar (BEVAGEN), used for treating advanced non-small cell lung cancer and metastatic colorectal cancer, produced under license from Innovent Biologics. Etana also produces Erythropoietin (EPO), marketed as RENOGEN, for anemia associated with chronic kidney disease. In response to the global pandemic, Etana developed an mRNA COVID-19 vaccine, InaRNAVac, through a technology transfer collaboration with Chinese firms, which received an Emergency Use Authorization from Indonesia's food and drug authority (BPOM) and halal certification. The company is also expanding into other vaccine platforms, including adenovirus technology and a PCV-13 vaccine for pneumonia in children. Its strategic collaborations with international pharmaceutical companies and local academic institutions, such as Universitas Gadjah Mada (UGM), are central to its strategy of accelerating product development through technology transfer and joint research.

Source: Dealroom company data

At a glance

Status
Operational
Employees
436
Open positions
None listed
Dealroom signal
52.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Vaccines, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing May 2025 $30M $120M International Finance Corporation ↗
LATE VCOther financing Mar 2023 — — Highlight Capital · German Investment Corporation · East Ventures · YunFeng Capital ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

PT Etana Biotechnologies Indonesia website traffic

Latest recorded traffic for PT Etana Biotechnologies Indonesia is 5.1K monthly website visits, up 41.7% over the last three months. PT Etana Biotechnologies Indonesia's team grew 8.5% over the past year.

Latest monthly visits5.1K 3-month web change+41.7% 1-year team growth+8.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Bonacia (Hefei) Pharmaceutical TechnologyBonacia is a CRO company specializing in clinical research , focusing on professional services for clinical research of innovative drugs, biological drugs and vaccines, and empowering the research and development of new drugs through clinical trial cloud platforms and AI China Operational 34 $14M $55M
Immorna BiotherapeuticsA biotechnology company focused on the development of mRNA-based therapeutics and vaccines Morrisville, United States Operational
Ab&B BiotechFocuses on the research and development of innovative human vaccines and multivalent vaccines Taizhou, China Operational
ZeaVaxxDeveloping a plant-derived nanoparticle that can improve animal vaccines West Lafayette, United States Operational
Normax BiomedNormax focus for 2022 is rapid growth in mRNA Vaccine R&D and manufacturing for sustainable pandemic preparedness Cork, Ireland Operational
CHA Vaccine InstituteTea vaccine research is a state-of-the-art biotech company developing vaccines and immunotherapys South Korea Operational
RVAC MedicinesMRNA platform company engaged in the research and development of innovative products such as vaccines for diseases Singapore Operational
Curevo VaccineCreating Next Generation Vaccines For Diseases Of Global Importance Seattle, United States Acquired
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

PT Etana Biotechnologies Indonesia in its local ecosystem

Live from Dealroom

The PT Etana Biotechnologies Indonesia office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • YunFeng Capital

Series B and later5 investors entered at this stage

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇮🇩 Indonesia98.7%
🇺🇸 United States0.3%
🇮🇳 India0.3%
🇦🇺 Australia0.3%
🇬🇧 United Kingdom0.3%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about PT Etana Biotechnologies Indonesia on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See PT Etana Biotechnologies Indonesia’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.